Nature Communications (Dec 2018)
SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4
- Konstantinos Tzelepis,
- Etienne De Braekeleer,
- Demetrios Aspris,
- Isaia Barbieri,
- M. S. Vijayabaskar,
- Wen-Hsin Liu,
- Malgorzata Gozdecka,
- Emmanouil Metzakopian,
- Hamish D. Toop,
- Monika Dudek,
- Samuel C. Robson,
- Francisco Hermida-Prado,
- Yu Hsuen Yang,
- Roya Babaei-Jadidi,
- Dimitrios A. Garyfallos,
- Hannes Ponstingl,
- Joao M. L. Dias,
- Paolo Gallipoli,
- Michael Seiler,
- Silvia Buonamici,
- Binje Vick,
- Andrew J. Bannister,
- Roland Rad,
- Rab K. Prinjha,
- John C. Marioni,
- Brian Huntly,
- Jennifer Batson,
- Jonathan C. Morris,
- Cristina Pina,
- Allan Bradley,
- Irmela Jeremias,
- David O. Bates,
- Kosuke Yusa,
- Tony Kouzarides,
- George S. Vassiliou
Affiliations
- Konstantinos Tzelepis
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- Etienne De Braekeleer
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- Demetrios Aspris
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- Isaia Barbieri
- Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrookes Hospital
- M. S. Vijayabaskar
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- Wen-Hsin Liu
- Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU)
- Malgorzata Gozdecka
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- Emmanouil Metzakopian
- UK Dementia Research Institute, University of Cambridge
- Hamish D. Toop
- School of Chemistry, University of New South Wales
- Monika Dudek
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- Samuel C. Robson
- School of Pharmacy and Biomedical Science, University of Portsmouth
- Francisco Hermida-Prado
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- Yu Hsuen Yang
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- Roya Babaei-Jadidi
- School of Chemistry, University of New South Wales
- Dimitrios A. Garyfallos
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- Hannes Ponstingl
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- Joao M. L. Dias
- Cancer Molecular Diagnosis Laboratory, National Institute for Health Research, Biomedical Research Centre, University of Cambridge
- Paolo Gallipoli
- Wellcome Trust–MRC Cambridge Stem Cell Institute, University of Cambridge
- Michael Seiler
- H3 Biomedicine Inc.
- Silvia Buonamici
- H3 Biomedicine Inc.
- Binje Vick
- Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU)
- Andrew J. Bannister
- Gurdon Institute and Department of Pathology
- Roland Rad
- Institute of Molecular Oncology and Functional Genomics, Department of Medicine II and TranslaTUM Cancer Center
- Rab K. Prinjha
- Epigenetics DPU, Immunoinflammation and Oncology TA Unit, GSK Medicines Research Centre
- John C. Marioni
- Cancer Research UK Cambridge Institute, University of Cambridge
- Brian Huntly
- Wellcome Trust–MRC Cambridge Stem Cell Institute, University of Cambridge
- Jennifer Batson
- Exonate Ltd, Milton Science Park
- Jonathan C. Morris
- School of Chemistry, University of New South Wales
- Cristina Pina
- Department of Haematology, University of Cambridge
- Allan Bradley
- Wellcome Trust Sanger Institute, Genome Campus
- Irmela Jeremias
- Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU)
- David O. Bates
- Exonate Ltd, Milton Science Park
- Kosuke Yusa
- Stem Cell Genetics, Wellcome Trust Sanger Institute
- Tony Kouzarides
- Gurdon Institute and Department of Pathology
- George S. Vassiliou
- Haematological Cancer Genetics, Wellcome Trust Sanger Institute
- DOI
- https://doi.org/10.1038/s41467-018-07620-0
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 13
Abstract
SRPK1, a kinase involved in splicing regulation, is a potential therapeutic target for AML patients. Here, the authors show that SRPK1 inhibition changes isoform levels of key epigenetic regulators, including BRD4, and it has anti-tumor effects specifically against MLL-rearranged AML cells.
